Analysis of shared heritability in common disorders of the brain
…, Y Kamatani, C Berr, L Letenneur, D Hannequin… - Science, 2018 - science.org
INTRODUCTION Brain disorders may exhibit shared symptoms and substantial
epidemiological comorbidity, inciting debate about their etiologic overlap. However, detailed …
epidemiological comorbidity, inciting debate about their etiologic overlap. However, detailed …
Voice onset time in aphasia, apraxia of speech and dysarthria: a review
…, M Jan, F Eustache, D Hannequin - Clinical linguistics & …, 2000 - Taylor & Francis
Voice onset time (VOT) is an objective temporal acoustic parameter defined as the time
between the release of the oral constriction for plosive production and the onset of vocal fold …
between the release of the oral constriction for plosive production and the onset of vocal fold …
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
The gene encoding apolipoprotein E (APOE) on chromosome 19 is the only confirmed
susceptibility locus for late-onset Alzheimer's disease. To identify other risk loci, we …
susceptibility locus for late-onset Alzheimer's disease. To identify other risk loci, we …
APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy
A Rovelet-Lecrux, D Hannequin, G Raux, NL Meur… - Nature …, 2006 - nature.com
We report duplication of the APP locus on chromosome 21 in five families with autosomal
dominant early-onset Alzheimer disease (ADEOAD) and cerebral amyloid angiopathy …
dominant early-onset Alzheimer disease (ADEOAD) and cerebral amyloid angiopathy …
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease
…, P Pastor, LA Cupples, ND Price, D Hannequin… - Nature …, 2017 - nature.com
We identified rare coding variants associated with Alzheimer's disease in a three-stage case–
control study of 85,133 subjects. In stage 1, we genotyped 34,174 samples using a whole …
control study of 85,133 subjects. In stage 1, we genotyped 34,174 samples using a whole …
[PDF][PDF] Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum
D Campion, C Dumanchin, D Hannequin… - The American Journal of …, 1999 - cell.com
To determine the prevalence of early-onset Alzheimer disease (EOAD) and of autosomal
dominant forms of EOAD (ADEOAD), we performed a population-based study in the city of …
dominant forms of EOAD (ADEOAD), we performed a population-based study in the city of …
APOE and Alzheimer disease: a major gene with semi-dominant inheritance
Apolipoprotein E (APOE) dependent lifetime risks (LTRs) for Alzheimer Disease (AD) are
currently not accurately known and odds ratios alone are insufficient to assess these risks …
currently not accurately known and odds ratios alone are insufficient to assess these risks …
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
Dominantly inherited Alzheimer's disease (DIAD) causes predictable biological changes
decades before the onset of clinical symptoms, enabling testing of interventions in the …
decades before the onset of clinical symptoms, enabling testing of interventions in the …
[HTML][HTML] APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases
…, C Ozsancak, J Pariente, C Paquet, D Hannequin… - PLoS …, 2017 - journals.plos.org
Background Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2
(PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD …
(PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD …
Frontotemporal dementia and its subtypes: a genome-wide association study
…, SF Cappa, I Le Ber, D Hannequin… - The Lancet …, 2014 - thelancet.com
Background Frontotemporal dementia (FTD) is a complex disorder characterised by a broad
range of clinical manifestations, differential pathological signatures, and genetic variability …
range of clinical manifestations, differential pathological signatures, and genetic variability …